What is Turnstone Biologics Financial Strength?
Turnstone Biologics has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate Turnstone Biologics's interest coverage with the available data.
As of today, Turnstone Biologics's Altman Z-Score is 0.00.
Competitive Comparison of Turnstone Biologics's Financial Strength
For the Biotechnology subindustry, Turnstone Biologics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turnstone Biologics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Turnstone Biologics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Turnstone Biologics's Financial Strength falls into.
Turnstone Biologics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Turnstone Biologics's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-20.69 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.69 Mil.
Turnstone Biologics's Interest Coverage for the quarter that ended in Mar. 2024 is
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Turnstone Biologics Corp has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Turnstone Biologics's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Turnstone Biologics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turnstone Biologics (Turnstone Biologics) Business Description
Traded in Other Exchanges
N/A
Address
9310 Athena Circle, Suite 300, La Jolla, CA, USA, 92037
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Executives
| Davis Jerel |
director, 10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Versant Ventures V, Llc |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Robert J Gould |
director |
C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
| Sammy J. Farah |
director, officer: President & CEO |
C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037 |
| Saryah Azmat |
officer: Chief Business Officer |
C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037 |
| Venkat Ramanan |
officer: Chief Financial Officer |
C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037 |
| Campisi Peter Joseph Jr. |
officer: Chief Legal Officer |
C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037 |
| Vijay Chiruvolu |
officer: Int. Chief Technology Officer |
C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037 |
| Versant Vantage Ii Gp, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Versant Vantage Ii Gp-gp, Llc |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Versant Vantage Ii, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Kanya Rajangam |
director |
C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Versant Ventures V Gp-gp (canada), Inc. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Michael F. Burgess |
director, officer: Interim Chief Medical Officer |
C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142 |
| Stewart Abbot |
officer: Chief Scientific Officer |
C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037 |
Turnstone Biologics (Turnstone Biologics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSBX has been successfully added to your